J0470 Insurance Policy Changes

HCPCS J0470 is officially defined as "Injection, dimercaprol, per 100 mg." HCPCS J0470 is referenced in 5 tracked payer policy changes from Blue Cross & Blue Shield of Mississippi, Aetna, and 1 other payer. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for HCPCS J0470 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

Blue Cross & Blue Shield of Mississippi · Effective Oct 1, 2026Medium impact
Chelation Therapy
Chelation therapy is considered medically necessary when based on blood levels and used to treat chronic iron overload due to blood transfusions or nontransfusion-dependent thalassemia, extreme conditions of metal toxicity, lead poisoning, Wilson's disease, emergency treatment of hypercalcemia, or control of ventricular arrhythmias or heart block associated with digitalis toxicity. Off-label applications, including atherosclerosis, Alzheimer disease, arthritis, multiple sclerosis, diabetes, autism, and Parkinson disease, are considered investigational. The 08/06/2026 review added Parkinson disease to the investigational list, and the 10/01/2026 update added ICD-10 codes R78.72 and Z77.013 to the code reference.
Aetna · Identified Aug 16, 2026Medium impact
Lyme Disease and other Tick-Borne Diseases (CPB 0215, reviewed 2026-07-21)
Aetna considers outpatient IV antibiotic therapy medically necessary for Lyme disease only when the clinical presentation is compatible with the disease and supported by two-tier serologic testing. Once Lyme disease is definitively diagnosed, an initial 4-week course of outpatient IV antibiotic therapy is medically necessary for persistent Lyme arthritis after failing a 4-week course of oral antibiotics, for moderate-to-severe cardiac or neurologic involvement, and for specified cases in pregnant women, and one repeat 4-week course is medically necessary with objective evidence of relapse, progression of organ damage, or a new focus or type of organ damage. Aetna considers IV antibiotic therapy for early Lyme disease, additional antibiotic therapy for post-treatment persistently fatigued patients, and a range of listed tests and treatments experimental, investigational, or unproven.
Aetna · Identified Aug 12, 2026Medium impact
Chelation Therapy (CPB 0234, reviewed 2026-02-11)
Deferoxamine mesylate is considered medically necessary for transfusional iron overload in members with chronic anemia when the pretreatment serum ferritin is greater than 1000 mcg/L, for aluminum toxicity in members undergoing dialysis, and for hereditary hemochromatosis when phlebotomy is not an option or the member had an unsatisfactory response to phlebotomy, and it must be prescribed by or in consultation with a hematologist or nephrologist. Other chelation therapy is considered medically necessary for conditions including aceruloplasminemia, biliary cirrhosis, Cooley's anemia, cystinuria, Diamond-Blackfan anemia, sickle cell anemia, Wilson's disease, secondary hemochromatosis, and heavy metal toxicity when symptoms are suggestive and toxicity is confirmed by laboratory testing. Chelation therapy for cancer, cardiovascular disease, neurodegenerative diseases, autism, ADHD, and mercury toxicity from dental amalgam fillings is considered experimental, investigational, or unproven.
Independence Blue Cross · Effective Aug 6, 2025Low impact
MA07.016c, Intravenous Chelation Therapy
Independence Blue Cross reissued MA07.016c on 08/06/2025 to reaffirm its continuing position on intravenous chelation therapy coverage. The policy adds 12 new ICD-10 codes related to gadolinium toxicity (T56.821A through T56.824S) and clarifies coverage criteria for medically necessary chelation therapy while designating off-label uses as experimental/investigational.
Independence Blue Cross · Effective Aug 6, 2025Low impact
07.00.02j, Intravenous Chelation Therapy
Independence Blue Cross reissued Policy 07.00.02j on intravenous chelation therapy, adding 12 new ICD-10 diagnosis codes for gadolinium toxicity (T56.821A through T56.824S) to the covered indications. The policy maintains existing coverage for chelation therapy for iron overload, metal poisoning, lead toxicity, Wilson's disease, digoxin toxicity, and hypercalcemia, with no changes to covered agents, billing codes, or clinical criteria.

Watch J0470

Get one email when a payer policy names J0470, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.

No account needed. We send a confirmation link first, and every email has a one-click stop link.

REFERENCE DATA

Payers with rules4

Payers requiring prior auth4

Centene · Effective December 31, 2025
Prior authorization required
Sunshine Health Title XIX, Title XXI, Managed Medical Assistance CMS-0057-F prior authorization requirements
Fidelis Care · Effective December 31, 2025
Prior authorization required
Fidelis Care CMS-0057-F prior authorization requirements
Cigna · Effective October 1, 2006
Prior authorization required
Cigna Master Precertification List

FREQUENTLY ASKED QUESTIONS

Does AmeriHealth Caritas require prior authorization for J0470?

AmeriHealth Caritas lists J0470 on AmeriHealth Caritas Louisiana prior authorization service list for medicaid managed plans. Verify with the payer before scheduling.

Does Centene require prior authorization for J0470?

Centene lists J0470 on Sunshine Health Title XIX, Title XXI, Managed Medical Assistance CMS-0057-F prior authorization requirements for medicaid managed plans (list dated December 31, 2025). Verify with the payer before scheduling.

Does Cigna require prior authorization for J0470?

Cigna lists J0470 on Cigna Master Precertification List for commercial plans (list dated October 1, 2026). Verify with the payer before scheduling.

Does Fidelis Care require prior authorization for J0470?

Fidelis Care lists J0470 on Fidelis Care CMS-0057-F prior authorization requirements for medicaid managed plans (list dated December 31, 2025). Verify with the payer before scheduling.

What insurance policy changes affect HCPCS J0470?

There are 5 tracked policy changes affecting HCPCS J0470, including updates from Blue Cross & Blue Shield of Mississippi, Aetna, Independence Blue Cross. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for HCPCS J0470?

Payers that have issued tracked updates for HCPCS J0470 include: Blue Cross & Blue Shield of Mississippi, Aetna, Independence Blue Cross.

How do I get notified when HCPCS J0470 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to HCPCS J0470. You will get an email when new policy changes reference this code: daily or weekly, your choice, on every plan.

Why do payers change policies for HCPCS J0470?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

See every payer rule for J0470

Prior authorization lists, coverage criteria, NCCI edits and Medicare coverage articles for J0470 in one place.

See every payer rule

All billing codes J3590 C9399 J3490 99215 99213 99202

Get alerts for changes like this

Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.

Create a free alert How Policy Monitoring works

Chelation Therapy

Lyme Disease and other Tick-Borne Diseases (CPB 0215, reviewed 2026-07-21)

Chelation Therapy (CPB 0234, reviewed 2026-02-11)

MA07.016c, Intravenous Chelation Therapy

07.00.02j, Intravenous Chelation Therapy

Prior authorization required

Prior authorization required

Prior authorization required

Does AmeriHealth Caritas require prior authorization for J0470?

Does Centene require prior authorization for J0470?

Does Cigna require prior authorization for J0470?

Does Fidelis Care require prior authorization for J0470?

What insurance policy changes affect HCPCS J0470?

Which payers have updated policy for HCPCS J0470?

How do I get notified when HCPCS J0470 policy changes?

Why do payers change policies for HCPCS J0470?